• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BrainsWay Ltd. (Amendment)

    2/21/24 6:01:45 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care
    Get the next $BWAY alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

    Amendment No. 2

     

    Under the Securities Exchange Act of 1934

     

    BrainsWay Ltd.

     

    (Name of Issuer)

     

    American Depositary Shares each representing two Ordinary Shares

     

    (Title of Class of Securities)

     

    10501L106

     

    (CUSIP Number)

     

    February 13, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed

     

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

     

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 10501L106

     

    1.

    Names of Reporting Persons. AIGH Capital Management, LLC

    I.R.S. Identification Nos. of above persons (entities only).

     

    27-4413262

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

     

    4.

    Citizenship of Place of Organization

     

    Maryland

    Number of Shares

    Beneficially

    Owned by Each

    Reporting
    Person

    With

    5.

    Sole Voting Power

     

    682,482

    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    682,482

    8.

    Shared Dispositive Power

     

     

    9.

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    682,482

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    4.1%

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

     

     

     

    CUSIP No. 10501L106

     

    1.

    Names of Reporting Persons. Orin Hirschman

    I.R.S. Identification Nos. of above persons (entities only).

     

     

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

     

    4.

    Citizenship of Place of Organization

     

    United States

    Number of Shares

    Beneficially

    Owned by Each

    Reporting
    Person

    With

    5.

    Sole Voting Power

     

    682,482

    6.

    Shared Voting Power

     

     

    7.

    Sole Dispositive Power

     

    682,482

    8.

    Shared Dispositive Power

     

     

    9.

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    682,482

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    4.1%

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

     

     

     

    ITEM 1:

     

      (a) Name of Issuer:

     

    Brainsway Ltd.

     

      (b) Address of Issuer’s Principal Executive Offices:

     

    19 Hartum St.

    Bynet Building 3rd Floor

    Har HaHotzvim

    Jerusalem 9777518 Israel

     

    ITEM 2:

     

      (a) Name of Person Filing:

     

        This Schedule 13G is being jointly filed by each of the following persons pursuant to Rule 13d-1 promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Act”):

     

      (i) AIGH Capital Management, LLC, a Maryland limited liability company (“AIGH CM”), as an Advisor or Sub-Advisor with respect to shares of Common Stock (as defined in Item 2(d) below) held by AIGH Investment Partners, L.P., WVP Emerging Manger Onshore Fund, LLC – AIGH Series, and WVP Emerging Manger Onshore Fund, LLC- Optimized Equity Series;
         
      (ii)

    AIGH Investment Partners, L.L.C., a Delaware limited liability company (“AIGH LLC”), with respect to shares of Common Stock (as defined in Item 2(d) below) directly held by it;

         
      (iii) Mr. Orin Hirschman (“Mr. Hirschman”), who is the Managing Member of AIGH Capital Management, LLC and president of AIGH LLC, with respect to shares of Common Stock (as defined in Item 2(d) below) indirectly held through AIGH CM, directly by AIGH LLC and Mr. Hirschman and his family directly.

     

    AIGH Capital Management LLC., AIGH Investment Partners LLC, and Mr. Hirschman are hereinafter sometimes collectively referred to as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

      (b) Address of Principal Business Office or, if None, Residence:

     

    The principal office and business address of AIGH Capital Management LLC, AIGH Investment Partners LLC, and Mr. Hirschman is:

     

    6006 Berkeley Avenue

    Baltimore MD 21209

     

      (c) Citizenship:

     

    See Item 2(a) above and Item 4 of each cover page.

     

      (d) Title of Class of Securities:

     

    American Depositary Shares each representing two Ordinary Shares

     

      (e) CUSIP Number:

     

    10501L106

     

     

     

     

    ITEM 3: IF THIS STATEMENT IS FILED PURSUANT TO §§240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
           
      (e) ☒ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ A non-U.S. institution, in accordance with §240.13d-1(b)(1)(ii)(J);
           
      (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).
           
         

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________________.

     

    ITEM 4: OWNERSHIP.

     

    See Items 5,6,7,8 and 9 of each cover page.

     

    ITEM 5: OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒

     

    ITEM 6: OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

     

    Not applicable.

     

    ITEM 7: IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

     

    Not applicable.

     

    ITEM 8: IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

     

    Not applicable.

     

    ITEM 9: NOTICE OF DISSOLUTION OF GROUP.

     

    Not applicable.

     

    ITEM 10: CERTIFICATIONS.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 21, 2024 By: /s/ Orin Hirschman
        Orin Hirschman,
       

    Individually and as (a) managing member

    of AIGH Capital Management LLC.: and (b)

    president of AIGH Investment Partners LLC.

     

     

    Get the next $BWAY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BWAY

    DatePrice TargetRatingAnalyst
    11/16/2023Outperform → Mkt Perform
    Raymond James
    3/3/2022$15.00Buy
    Loop Capital
    11/29/2021$14.00 → $15.00Buy
    HC Wainwright & Co.
    8/12/2021$17.00 → $14.00Buy
    HC Wainwright & Co.
    7/19/2021$17.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BWAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company's Growth Strategy and Deep TMS™ Treatment December 1, 2025

    BURLINGTON, Mass. and JERUSALEM, Nov. 25, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today announced that it will host a virtual Analyst & Investor Day on Monday, December 1, 2025 at 10:00 AM ET, during which company management will highlight various aspects of BrainsWay's growth strategy. The event will feature Owen Scott Muir, MD, DFAACAP (Co-Founder, Chief Medical Officer, Radial), who will discuss the significant unmet need for various conditions and his clinical experience utilizing Deep TMS™, and Michael Gershenzon, CEO of Stella MSO, a management services organi

    11/25/25 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder

    BURLINGTON, Mass. and JERUSALEM, Nov. 17, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today announced the launch of a multicenter clinical trial investigating the use of its novel Deep TMS 360™ system in individuals with Alcohol Use Disorder (AUD). AUD represents a major economic and health burden, affecting about 29 million Americans (10% of those aged 12+) and, despite available treatments, up to 60% of patients relapse within 3-6 months. This study will mark the first multicenter clinical trial utilizing BrainsWay's next-generation multichannel TMS platform, represen

    11/17/25 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21

    BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 13, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted a label expansion for the Deep Transcranial Magnetic Stimulation (Deep TMS™) system making the treatment available as an adjunct therapy for adolescents aged 15 to 21 years suffering from major depressive disorder (MDD). "The FDA's clearance of this expanded label enables access to Deep TMS™ for the critically important adolescent patient population, which is often underserved

    11/13/25 6:00:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    $BWAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Brainsway downgraded by Raymond James

    Raymond James downgraded Brainsway from Outperform to Mkt Perform

    11/16/23 7:31:55 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    Loop Capital initiated coverage on BrainsWay with a new price target

    Loop Capital initiated coverage of BrainsWay with a rating of Buy and set a new price target of $15.00

    3/3/22 4:42:28 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on BrainsWay with a new price target

    HC Wainwright & Co. reiterated coverage of BrainsWay with a rating of Buy and set a new price target of $15.00 from $14.00 previously

    11/29/21 6:24:14 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    $BWAY
    SEC Filings

    View All

    SEC Form 6-K filed by BrainsWay Ltd.

    6-K - Brainsway Ltd. (0001505065) (Filer)

    11/17/25 7:30:03 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by BrainsWay Ltd.

    6-K - Brainsway Ltd. (0001505065) (Filer)

    11/13/25 6:00:09 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by BrainsWay Ltd.

    6-K - Brainsway Ltd. (0001505065) (Filer)

    11/12/25 7:00:18 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    $BWAY
    Financials

    Live finance-specific insights

    View All

    BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights

    Revenue increased 29% to $13.5 million in Q3 2025 as compared with Q3 2024 Operating income totaled $1.3 million and Adjusted EBITDA rose approximately 80% to $2.0 million in Q3 2025, as compared with Q3 2024 Remaining performance obligations increased to $65 million FDA cleared an accelerated protocol for Deep TMS treatment of patients with major depressive disorder (MDD) Raised midpoint of full-year 2025 Revenue and EBITDA guidance Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatm

    11/11/25 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025

    BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, November 11, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the financial results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, November 11, 2025Time:8:30 AM Eastern TimeUnited States:1-8

    10/28/25 8:00:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health

    BURLINGTON, Mass. and JERUSALEM, Aug. 20, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has entered into a strategic equity financing agreement with Axis Management Company, Inc. ("Axis Integrated Mental Health" or "Axis"), a management services organization servicing several mental health clinics in Colorado. Under the terms of the agreement, BrainsWay will invest $2.3 million initially, and an additional potential $1 million milestone-based investment, for a minority position in Axis in the form of a preferred, annually c

    8/20/25 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    $BWAY
    Leadership Updates

    Live Leadership Updates

    View All

    MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

    MindWalk Holdings Corp.™ ("MindWalk," "Company," "we" or "us") (NASDAQ:HYFT), bio-native AI company today announces the appointment of industry veteran R. Scott Areglado as Chief Financial Officer (CFO), effective October 20, 2025. "Scott's extensive experience leading financial strategy for high-growth, publicly traded healthcare and technology companies makes him an ideal addition to our executive team," said Dr. Jennifer Bath, MindWalk CEO. "His proven ability to strengthen financial systems, execute disciplined growth initiatives, and communicate effectively with the investment community will be instrumental as we scale our Bio-Native AI platform globally." Mr. Areglado brings more

    10/21/25 8:28:00 AM ET
    $BWAY
    $HYFT
    $ICAD
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    BrainsWay Appoints Richard A. Bermudes, M.D. as Chief Medical Officer

    BURLINGTON, Mass. and JERUSALEM, Aug. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Richard A. Bermudes, M.D. as Chief Medical Officer (CMO), effective September 1, 2024. Dr. Aron Tendler, M.D., who has served as CMO since 2015, will continue to serve as a collaborator on important strategic research projects. "We are excited to have Richard join our team to lead and shape BrainsWay's clinical strategy and product roadmap. His extensive experience with TMS and brain stimulation therapies as a practicing phys

    8/29/24 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    Murchinson Takes Action to Replace Board of Directors of Nano Dimension at Upcoming Annual General Meeting

    Highlights Entrenchment Tactics Taken by the Board Before and Following March Special Meeting Where Shareholders Overwhelmingly Supported Murchinson's Case for Change – Including the Removal of CEO and Chairman Yoav Stern From the Board Puts Forward Proposals to Improve Company's Failed Corporate Governance by Seeking to Remove All Current Directors and Appoint Five New, Experienced and Independent Nominees Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 5.9% of the outstanding shares of Nano Dimension Ltd., a company incorporated in Israel (NASDAQ:NNDM) ("Nano Dimension" or th

    8/3/23 3:00:00 PM ET
    $BWAY
    $INSG
    $MCK
    Medical/Dental Instruments
    Health Care
    Telecommunications Equipment
    Telecommunications

    $BWAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BrainsWay Ltd.

    SC 13G/A - Brainsway Ltd. (0001505065) (Subject)

    11/14/24 1:33:58 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by BrainsWay Ltd.

    SC 13G/A - Brainsway Ltd. (0001505065) (Subject)

    11/14/24 1:32:48 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by BrainsWay Ltd.

    SC 13D - Brainsway Ltd. (0001505065) (Subject)

    11/13/24 6:09:51 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care